Kawakami Y and Rosenberg SA. Immunobiology of melanoma antigens MART-1 and gp100 and their use in immunotherapy. Intern Rev Immunol.14(2-3):173-192.1997
Sakai C, Kawakami Y, Law LW, Furumura M and Hearing VJ Jr. Melanosomal proteins as melanoma-specific immune targets. Melanoma Res.7(2):83-95.1997 Apr
Kang X, Robbins PF, Fitzgerald EB, Wang RF and Rosenberg SA, Kawakami Y. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. Cancer Res.57(2):202-205.1997 Jan
Kawakami Y, Battles JK, Kobayashi T, Ennis W, Wang X, Tupesis JP, Marincola FM, Robbins PF, Hearing VJ, Gonda MA and Rosenberg SA. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: Use in the characterization of the human melanoma antigen MART-1. J Immunol Methods.202(1):13-25.1997 Mar
Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A and Celis E. Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol.158(4):1796-1802.1997 Feb
Robbins PF, El-Gamil M, Li YF, Fitzgerald EB, Kawakami Y and Rosenberg SA. The intronic region of an imcompletely-spliced gp100 gene transcript encodes an epitope recognized by melanoma reactive tumor infiltrating lymphocytes. J Immunol.159(1):303-308.1997 Jul
Kawakami Y and Rosenberg SA. Human tumor antigens recognized by T cells. Immunologic Res.16(4):313-339.1997 Nov
Kageshita T, Kawakami Y, Hirai S and Ono T. Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother.20(6):460-465.1997 Nov